关键信息
-
基因名
UCHL5
- 应用
-
别名
UCHL5；UCH37；Ubiquitin carboxyl-terminal hydrolase isozyme L5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y5K5
-
表达区间
1-326aa
-
氨基酸序列
MTGNAGEWCLMESDPGVFTELIKGFGCRGAQVEEIWSLEPENFEKLKPVHGLIFLFKWQPGEEPAGSVVQDSRLDTIFFAKQVINNACATQAIVSVLLNCTHQDVHLGETLSEFKEFSQSFDAAMKGLALSNSDVIRQVHNSFARQQMFEFDTKTSAKEEDAFHFVSYVPVNGRLYELDGLREGPIDLGACNQDDWISAVRPVIEKRIQKYSEGEIRFNLMAIVSDRKMIYEQKIAELQRQLAEEPMDTDQGNSMLSAIQSEVAKNQMLIEEEVQKLKRYKIENIRRKHNYLPFIMELLKTLAEHQQLIPLVEKFEKHFEKTLLGK
-
分子量
53.4kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
UCHL5 (Ubiquitin C-terminal hydrolase L5) is a deubiquitinating enzyme that plays a crucial role in the regulation of protein degradation pathways, particularly in the context of the ubiquitin-proteasome system. This enzyme is involved in the removal of ubiquitin moieties from tagged proteins, thereby influencing various cellular processes, including cell cycle regulation, DNA repair, and signal transduction. Dysregulation of UCHL5 has been implicated in several diseases, notably cancer, where altered protein degradation pathways can lead to uncontrolled cell proliferation and survival. Research has focused on characterizing the structure and function of UCHL5, as well as its interactions with other cellular proteins. Understanding its mechanism of action could provide valuable insights into novel therapeutic interventions targeting ubiquitin-mediated pathways. Additionally, UCHL5 has been identified as a potential biomarker for certain cancers, making it a point of interest in both basic and clinical research. Studies involving the recombinant expression of UCHL5 protein have enabled researchers to explore its enzymatic activity and substrate specificity in detail, contributing to the development of potent inhibitors or modulators that could enhance therapeutic strategies in cancer treatment and other pathologies associated with ubiquitin system dysregulation.
